48 related articles for article (PubMed ID: 38708153)
1. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
2. Management of relapsed-refractory diffuse large B cell lymphoma.
Raut LS; Chakrabarti PP
South Asian J Cancer; 2014 Jan; 3(1):66-70. PubMed ID: 24665451
[TBL] [Abstract][Full Text] [Related]
3. Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study.
Singh C; Jandial A; Jain A; Lad D; Khadwal A; Basher R; Bal A; Malhotra P; Prakash G
Indian J Hematol Blood Transfus; 2024 Apr; 40(2):231-236. PubMed ID: 38708153
[TBL] [Abstract][Full Text] [Related]
4. Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma.
Jeong SY; Yoon SE; Cho D; Kang ES; Cho J; Kim WS; Kim SJ
Front Oncol; 2022; 12():1071281. PubMed ID: 36741719
[TBL] [Abstract][Full Text] [Related]
5. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
6. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant.
Ladbury C; Kambhampati S; Othman T; Hao C; Chen L; Wong J; Cao T; Herrera A; Mei M; Dandapani S
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):594-601. PubMed ID: 35176414
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y; Kanemasa Y; Sasaki Y; Sei M; Matsuo T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
Cancer Med; 2023 Sep; 12(17):17808-17821. PubMed ID: 37635630
[TBL] [Abstract][Full Text] [Related]
9. Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program.
Radhakrishnan VS; Pincha R; Raina V; Garg JK; Nag A; Bhave SJ; Achari R; Dey D; Arun I; Lateef Z; Vinarkar SS; Parihar M; Sen S; Mishra DK; Chandy M; Nair R
Indian J Hematol Blood Transfus; 2022 Dec; 39(4):1-5. PubMed ID: 36590655
[TBL] [Abstract][Full Text] [Related]
10. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
11. Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.
Daneels W; Rosskamp M; Macq G; Saadoon EI; De Geyndt A; Offner F; Poirel HA
Front Oncol; 2022; 12():824704. PubMed ID: 35299736
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Large B-Cell Lymphoma.
Sehn LH; Salles G
N Engl J Med; 2021 Mar; 384(9):842-858. PubMed ID: 33657296
[TBL] [Abstract][Full Text] [Related]
14. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden.
Harrysson S; Eloranta S; Ekberg S; Enblad G; Jerkeman M; Wahlin BE; Andersson PO; Smedby KE
Blood Cancer J; 2021 Jan; 11(1):9. PubMed ID: 33414443
[TBL] [Abstract][Full Text] [Related]
15. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
